Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT00883688 : Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma
PhasePhase 2
AgesMin: N/A Max: 21 Years
Eligibility
Inclusion Criteria:

1. Age: Patient must be < or = 21 years of age.

2. Tumor: Patients must have recurrent or refractory intracranial ependymoma (including
myxopapillary, clear cell, papillary, tanycytic, and anaplastic ependymoma) or
subependymoma. Patients with primary diagnosis of intracranial ependymoma with spinal
cord metastases or relapse are eligible. The diagnosis must be confirmed by the CERN
enrolling site's pathologist on tissue from either the initial presentation or time
of recurrence prior to registration. For central pathology review and trial
biological studies, submission of a paraffin block with tumor measuring at least 1 cm
x 1 cm in area is preferred, but 15 x 5micro m unstained sections on slides may be
provided by the referring laboratory instead. Tissue must be submitted within 60 days
after enrollment for central processing and analysis.

3. Patients must have measureable disease which is defined as at least one measurable
lesion that can be accurately measured in 2 planes. Diffuse leptomeningeal
involvement ("sugar coating") that does not allow measurement of at least one lesion
in 2 planes will not be considered measurable disease.

4. Patients may have had any number of prior treatment regimens (including biologic)
before or after radiotherapy. Patients may not have previously been treated with
Bevacizumab or Lapatinib. Gliadel wafers must be approved by CERN PI (Project Leader,
Co-Leader and Protocol PI).

5. Neurological Deficits: Patients with neurological deficits should have deficits that
are stable or improving for a minimum of 1 week prior to registration.

6. Performance Score: Karnofsky Performance Scale (KPS for > 16 years of age) or Lansky
Performance Score (LPS for < or = 16 years of age) > or = 50 assessed within 2 weeks
prior to registration.

7. Evidence of recovery from any prior chemotherapy. No myelosuppressive anticancer
chemotherapy or biological therapy within 3 weeks (6 weeks if a nitrosourea or
mitomycin C agent) prior to registration.

8. Prior/Concurrent Therapy: XRT: Patients must have had prior radiation therapy for
treatment of their ependymoma. XRT must be > or = 3 months prior to registration for
craniospinal irradiation (> or = 18 Gy); > or = 4 weeks for local radiation to
primary tumor; and > or = 2 weeks prior to registration for focal irradiation to
symptomatic metastatic sites.

9. Prior/Concurrent Therapy: Bone Marrow Transplant: > or = 3 months prior to
registration for autologous bone marrow/stem cell transplant.

10. Prior/Concurrent Therapy: Anti-convulsants: Patients with seizure disorder may be
enrolled if well controlled. Patients receiving enzyme-inducing anticonvulsants are
not eligible for this study. Patients must be off EIACD for at least 2 weeks prior to
registration.

11. Prior/Concurrent Therapy: Corticosteroids: Patients who are receiving corticosteroids
must be on a stable or decreasing dose for at least 1 week prior to registration.

12. Prior/Concurrent Therapy: Growth Factors: Off all colony forming growth factor(s) >
or = 2 weeks prior to registration (G-CSF, GM-CSF, Erythropoietin).

13. Patients must not have received: CYP3A4 inhibitors within seven (7) days prior to
registration on protocol and for the duration of the study. However, amiodarone,
another CYP3A4 inhibitor, should have been discontinued 6 months prior to
registration and for the duration of the study.

14. Patient must not have received: CYP3A4 inducers within fourteen (14) days prior to
registration and for the duration of the study.

15. Patient must not have received: Cimetidine within 48 hours prior and for the duration
of the study.

16. The following laboratory values must be assessed within 7 days prior to registration
and must be repeated if initial labs were done greater than (>seven) (7) calendar
days prior to the start of therapy. Organ Function: Must have adequate organ function
and marrow function as defined by the following parameters: Bone Marrow: Absolute
neutrophil count >or =1000microliter, Platelets > or = 100,000 microliter
(transfusion independent), Hemoglobin >or =8.0 g/dL. Renal: Serum creatinine 1.5 times upper limit of institutional for age or GFR>or = 70ml/min/1.73m2 Hepatic:
Total bilirubin < or = 1.5 times upper limit of normal for age: SGPT (ALT)<2.5x
institutional upper limit of normal for age and albumin > or = 2g/dL. No overt renal,
hepatic, cardiac or pulmonary disease.

17. No overt renal, hepatic, cardiac or pulmonary disease.

18. Adequate cardiac function, assessed within 2 weeks prior to registration, defined as:
shortening fraction of > or = 27% by echocardiogram, or ejection fracture (LVEF) > or
= 50% by gated radionucleotide study.

19. Adequate pulmonary function, assessed within 2 weeks prior to registration, defined
as: no evidence of dyspnea at rest, no exercise intolerance, and a pulse oximetry >
94% if there is clinical indication for determination.

20. Signed informed consent according to institutional guidelines must be obtained.

21. Women of child-bearing potential and men must agree to use adequate contraception
(hormonal or barrier method of birth control; abstinence) prior to study entry and
for the duration of study participation. Should a woman become pregnant or suspect
she is pregnant while participating in this study, she should inform her treating
physician immediately and will be removed from the study.

22. Patient must begin therapy within 7 calendar days of registration.

Exclusion Criteria:

1. Patients may not have previously been treated with Bevacizumab or Lapatinib.

2. Patients with any significant medical illnesses that, in the investigator's opinion,
cannot be adequately controlled with appropriate therapy or would compromise the
patient's ability to tolerate this therapy.

3. Patients with any disease that would obscure toxicity or dangerously alter drug
metabolism.

4. Patients receiving any other anticancer or experimental drug therapy.

5. Patients with uncontrolled infection.

6. Patients on enzyme inducing anticonvulsants.

7. Patients with > / = Grade 2 uncontrolled hypertension.

8. History of a stroke, myocardial infarction, or unstable angina in the previous 6
months.

9. Evidence of a bleeding diathesis, coagulopathy or PT INR>1.5.

10. Patients who require the use of therapeutic anti-coagulation: except as required to
maintain patency of preexisting permanent vascular catheter.

11. Pre-existing coagulopathy or thrombosis: Patients must not have been previously
diagnosed with a deep venous or arterial thrombosis (including pulmonary embolism),
and must not have a known thrombophilic condition.

12. Patients must have recovered from any surgical procedure before enrolling on this
study.

13. History of an abdominal fistula, GI perforation, or intra-abdominal abscess within
previous 6 months.

14. A serious, non healing wound, ulcer, or bone fracture.

15. Evidence of a new intracranial or intratumoral hemorrhage that is larger than a
punctuate size on baseline MRI obtained within 14 days prior to study registration.

16. If there is proteinuria present on dipstick, patients must have a 24 hour urine
collection. Patients are excluded if they have >500 mg protein on 24 hour urine
collection.

17. Pregnancy: Females of childbearing potential must have negative serum or urine
pregnancy test within 7 days prior to study entry. The effects of lapatinib on the
developing human fetus are unknown. However, bevacizumab is known to be teratogenic
and detrimental to fetal development and endometrial proliferation, thereby having a
negative effect on fertility.

18. Breastfeeding: Because there is an unknown but potential risk for adverse events in
nursing infants secondary to treatment of the mother with lapatinib of bevacizumab,
breastfeeding should be discontinued if the mother is treated on this study.
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT00883688      |      Link to official Clinicaltrials.gov listing
Locations



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740